# Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Source: https://onco.cc/trials/nct06081959/  
OnCo record `nct06081959` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT06081959 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 376 participants planned, started 2023-10-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: SKB264, Eribulin, Capecitabine, Gemcitabine and Vinorelbine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06081959
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter Phase 3 Study of SKB264 Versus Treatment of Physician's Choice (TPC) in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 376

## Sources

- ClinicalTrials.gov NCT06081959: https://clinicaltrials.gov/study/NCT06081959

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Eribulin](https://onco.cc/drugs/eribulin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct06081959.json